MD Anderson surgeons have found a way to reduce pain and opioid use for lung cancer patients undergoing a lung resection. A recent study led by David Rice, M.B. BCh, professor of Thoracic and Cardiovascular Surgery, and published in the Annals of Surgery, showed that using an Enhanced Recovery After Surgery (ERAS) pathway employing a long-acting local anesthetic (liposomal bupivacaine)...
In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy...
MD Anderson has created a new research platform to drive the discovery of new therapeutic agents for patients with leukemia by investigating...
A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of Texas MD Anderson Cancer Center demonstrated significantly increased progression-free survival in multiple myeloma patients.
The study, which followed 202 patients, compared busulfan with melphalan versus melphalan alone. Progression-free survival was 65 months for patients receiving combination...
Cell-based immunotherapies such as chimeric antigen receptors (CAR T), T-cell receptor (TCR) engineered T cells, tumor-infiltrating lymphocytes...
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge...
Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping...
The biopharmaceutical drug blinatumomab is more effective for the treatment of relapsed or treatment-resistant acute lymphoblastic leukemia...
In the modern world of biomedical research, collaborations between academic institutions and pharmaceutical and biotech companies have become...
Chemistry professor Bindu Chakravarty rarely missed a day teaching at Houston Community College. So when she called in sick one morning, it...